4.6 Article

Prognostic value of glycated hemoglobin in colorectal cancer

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 45, Pages 9984-9993

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v22.i45.9984

Keywords

Colorectal cancer; Type 2 diabetes; Glycated hemoglobin; Insulin resistance; Prognostic value

Funding

  1. European Social Fund, under the Italian Ministry of Education, University and Research [PON03PE_00146_1/10 BIBIOFAR, CUP B88F12000730005]

Ask authors/readers for more resources

AIM To investigate the clinical significance of routinely used glycemic parameters in a cohort of colorectal cancer (CRC) patients. METHODS Pre-treatment fasting blood glucose, insulin, HbA1c and homeostasis model of risk assessment (HOMA-IR) were retrospectively evaluated in a case-control study of 224 CRC and 112 control subjects matched for sex, obesity and diabetes frequency and blood lipid profile. Furthermore, the prognostic value of routinely used glycemic parameters towards progression-free (PFS) and overall survival (OS) was prospectively evaluated. RESULTS Fasting blood glucose, insulin, HOMA-IR and HbA1c (all P < 0.0001) levels were higher in non-diabetic CRC patients compared with obesity-matched controls. All parameters were associated with increased CRC risk at ROC analysis, but no relationship with clinical-pathological variables or survival outcomes was observed for glycemia, insulinemia or HOMA-IR. Conversely, advanced CRC stage (P = 0.018) was an independent predictor of increased HbA1c levels, which were also higher in patients who had disease progression compared with those who did not (P = 0.05). Elevated HbA1c levels showed a negative prognostic value both in terms of PFS (HR = 1.24) and OS (HR = 1.36) after adjustment for major confounders, which was further confirmed in a subgroup analysis performed after exclusion of diabetic patients. CONCLUSION HbA1c might have a negative prognostic value in CRC, thus suggesting that glycemic metabolic markers should be carefully monitored in these patients, independently of overt diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Irinotecan or Oxaliplatin: Which is the First Move for the Mate?

Cristina Morelli, Vincenzo Formica, Silvia Riondino, Antonio Russo, Patrizia Ferroni, Fiorella Guadagni, Mario Roselli

Summary: The study discusses the potential link between RAS, BRAF, and microsatellite instability with the efficacy of oxaliplatin and irinotecan in chemotherapy. KRAS mutation increases sensitivity to oxaliplatin, while limited data is available on the efficacy of BRAF mutations. Irinotecan shows enhanced cytotoxicity to MSI cell lines due to the involvement of mismatch repair components in DNA repair processes.

CURRENT MEDICINAL CHEMISTRY (2021)

Review Oncology

A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma

V. Formica, C. Morelli, A. Patrikidou, KK. Shiu, A. Nardecchia, J. Lucchetti, M. Roselli, HT. Arkenau

Summary: PD-L1 positive patients derive significant survival benefit from immune checkpoint inhibitors in gastro-oesophageal junction/gastric cancer, with other predictors needed for further refining patient selection.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Article Medicine, General & Internal

Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients-The Importance of Tissue/Plasma Discordant Cases

Vincenzo Formica, Jessica Lucchetti, Elena Doldo, Silvia Riondino, Cristina Morelli, Renato Argiro, Nicola Renzi, Daniele Nitti, Antonella Nardecchia, Emanuela Dell'Aquila, Patrizia Ferroni, Fiorella Guadagni, Giampiero Palmieri, Augusto Orlandi, Mario Roselli

Summary: This study demonstrates that mutational analysis through plasma can better predict survival outcomes for colorectal cancer patients, compared to relying solely on tumor tissue analysis. Plasma mutations further refine prognosis and can help guide clinical management.

JOURNAL OF CLINICAL MEDICINE (2021)

Meeting Abstract Oncology

Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling

C. Morelli, V. Formica, E. Doldo, S. Riondino, M. Rofei, G. Palmieri, A. Orlandi, M. Roselli

ANNALS OF ONCOLOGY (2021)

Article Cell Biology

Low level of plasminogen increases risk for mortality in COVID-19 patients

David Della-Morte, Francesca Pacifici, Camillo Ricordi, Renato Massoud, Valentina Rovella, Stefania Proietti, Mariannina Iozzo, Davide Lauro, Sergio Bernardini, Stefano Bonassi, Nicola Di Daniele

Summary: This study found a significant association between low plasminogen levels and inflammatory markers, coagulation markers, and organ dysfunction markers in COVID-19 patients. Plasminogen may play a vital role in controlling the complex mechanisms behind the complications of COVID-19, serving as both a biomarker for prognosis and a potential therapeutic target.

CELL DEATH & DISEASE (2021)

Review Nutrition & Dietetics

Polyphenols and Ischemic Stroke: Insight into One of the Best Strategies for Prevention and Treatment

Francesca Pacifici, Valentina Rovella, Donatella Pastore, Alfonso Bellia, Pasquale Abete, Giulia Donadel, Silvia Santini, Heinz Beck, Camillo Ricordi, Nicola Di Daniele, Davide Lauro, David Della-Morte

Summary: This article reviewed the association between polyphenols and stroke protection, including prevention, acute phase effects, and rehabilitation. These compounds have clinical relevance in reducing vascular risk factors for stroke.

NUTRIENTS (2021)

Review Biochemistry & Molecular Biology

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Giovanni Maria Iannantuono, Francesco Torino, Roberto Rosenfeld, Simona Guerriero, Manuela Carlucci, Stefano Sganga, Barbara Capotondi, Silvia Riondino, Mario Roselli

Summary: Precision medicine has ushered in a new era in anti-cancer drug development by focusing on biomarkers predictive of treatment response regardless of tumor histology. Although there have been histology-agnostic drugs approved by the FDA in recent years, the efficacy data for metastatic castration-resistant prostate cancer patients is still limited. Therefore, large multi-institutional registries are needed to collect real-world data.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Health Care Sciences & Services

MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review

Roberto Rosenfeld, Silvia Riondino, Vincenzo Formica, Francesco Torino, Eugenio Martuscelli, Mario Roselli

Summary: Breast cancer is the most common type of cancer in women, and the chemotherapy drug doxorubicin can cause heart toxicity. Early diagnosis of heart toxicity is important to prevent complications. Non-coding RNA, specifically microRNA and circular RNA, are being researched as potential biomarkers for early detection. Further studies are needed to understand the mechanisms and develop reliable detection methods.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Review Oncology

Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Valentina Russo, Eleonora Lallo, Armelle Munnia, Miriana Spedicato, Luca Messerini, Romina D'Aurizio, Elia Giuseppe Ceroni, Giulia Brunelli, Antonio Galvano, Antonio Russo, Ida Landini, Stefania Nobili, Marcello Ceppi, Marco Bruzzone, Fabio Cianchi, Fabio Staderini, Mario Roselli, Silvia Riondino, Patrizia Ferroni, Fiorella Guadagni, Enrico Mini, Marco Peluso

Summary: Metastatic colorectal cancer (mCRC) has a high incidence and mortality rate. Innovative biomarkers have been developed for predicting treatment response. By analyzing specific narrative publications, this study examines the ability of learning methods to build predictive models for mCRC patients, either for chemotherapy alone or combined with targeted therapy. The results show promising outcomes in predicting treatment response or toxic side-effects. Radiomics and molecular biomarkers are able to accurately identify responders and non-responders in the majority of patients.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Association of LTA and SOD Gene Polymorphisms with Cerebral White Matter Hyperintensities in Migraine Patients

Patrizia Ferroni, Raffaele Palmirotta, Gabriella Egeo, Cinzia Aurilia, Maria Giovanna Valente, Antonella Spila, Alberto Pierallini, Piero Barbanti, Fiorella Guadagni

Summary: The study investigates the association between white matter hyperintensities (WMHs) and genetic pro-inflammatory/pro-oxidative status in migraine patients. The results show no significant difference in gene polymorphisms between patients and controls. However, specific alleles of the lymphotoxin alpha (LTA) and superoxide dismutase 1 (SOD1) genes are associated with WMHs. This suggests that an imbalance between pro-inflammatory/pro-oxidative and antioxidant events may contribute to the development of WMHs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Medicine, General & Internal

Admission eGFR predicts in-hospital mortality independently of admission glycemia and C-peptide in patients with type 2 diabetes mellitus and COVID-19

Marco Infante, Massimo Pieri, Santina Lupisella, Ali Mohamad, Sergio Bernardini, David Della-Morte, Andrea Fabbri, Alberto De Stefano, Marco Iannetta, Lorenzo Ansaldo, Angela Crea, Massimo Andreoni, Maria Morello

Summary: Type 2 diabetes mellitus and impaired kidney function are linked to a higher risk of adverse outcomes in COVID-19. This study found that admission estimated glomerular filtration rate and white blood cell count were significantly associated with in-hospital mortality among patients with diabetes and COVID-19.

CURRENT MEDICAL RESEARCH AND OPINION (2023)

Article Immunology

Prolonged clinical remission of type 1 diabetes sustained by calcifediol and low-dose basal insulin: a case report

Marco Infante, Laura Vitiello, Andrea Fabbri, Camillo Ricordi, Nathalia Padilla, Francesca Pacifici, Pasquale Di Perna, Marina Passeri, David Della-Morte, Massimiliano Caprio, Luigi Uccioli

Summary: We describe a case of a 22-year-old Italian man with new-onset type 1 diabetes who experienced an unusually prolonged clinical remission phase (31 months). The patient was treated with calcifediol and low-dose insulin, resulting in the maintenance of residual beta-cell function and clinical remission. This may be attributed to the immunoregulatory properties of calcifediol.

IMMUNOTHERAPY (2023)

Article Oncology

Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?

Silvia Riondino, Vincenzo Formica, Elena Valenzi, Cristina Morelli, Valeria Flaminio, Ilaria Portarena, Francesco Torino, Mario Roselli

Summary: This study aimed to identify a cut-off point of body mass index (BMI) that would have a significant prognostic impact on stage I-II BC patients receiving AI treatment. The results showed that a BMI cut-off >29 was associated with a deteriorating disease-free survival (DFS) in AI-treated BC patients, indicating that obesity is a risk factor for recurrence in breast cancer.

CURRENT ONCOLOGY (2023)

No Data Available